OMC heads into its July 28 earnings report as one of the more heavily shorted names in the advertising sector, with the short position sitting well above typical levels even as bears show some signs of fatigue.
Short interest at nearly 15% of free float is the central positioning story. The absolute figure has drifted about 5% lower over the past month — from a peak near 31 million shares in mid-June to roughly 28.7 million today — but the retreat has stalled in recent days, with a small uptick recorded on July 23. The borrow market offers no squeeze signal: availability is generous at roughly 491%, meaning shares available to lend outnumber existing short positions by nearly five to one, and cost to borrow has eased to just 0.51%. Bears can add to positions cheaply and without friction if the print disappoints.
Options positioning has shifted in a notably more constructive direction. The put/call ratio has dropped to 1.15, almost a full standard deviation below its 20-day average of 1.29 — the opposite of what you'd expect from a market bracing for bad news. That's a meaningful turn from late June, when the ratio briefly pushed above 1.7. The stock has moved with it: OMC is up 9% over the past month to $79.66, though it gave back about 2.5% on the week, suggesting some hesitation right at the open of earnings week. Peer names were broadly weaker on the day — fell 0.5%, dropped 1.3%, and shed nearly 5% — making OMC's +2.3% session Friday a relative standout.
The analyst community is split but meaningfully skewed to the upside, with a consensus mean target of $102.75 against the current $79.66 price — implying roughly 29% upside. Goldman Sachs initiated with a Buy and a $146 target in early June, though that target sits well above the peer consensus and warrants context. Morgan Stanley holds Equal-Weight with an $83 target, barely above the current price, while Citi trimmed its target from $115 to $105 after last quarter's results but maintained Buy. Bank of America sits at Underperform. The core bull case rests on deal-related synergies from the IPG integration and a 12-month forward EPS growth rank in the 95th percentile of the ORTEX universe. Bears focus on execution risk around that same integration, modest near-term revenue visibility, and a quality factor that ranks in the low-to-mid 40s.
Insider activity adds a cautious undercurrent. CEO John Wren, CFO Philip Angelastro, and President Daryl Simm all sold shares in May — collectively over $6.5 million in stock — with net insider selling over the trailing 90 days reaching roughly $7.6 million. These were low-significance transactions by ORTEX scoring, and the cluster timing was consistent with routine plan sales, but the direction is uniformly outward. Monday's print will test whether the IPG integration thesis is delivering tangible revenue and margin uplift — or whether the near-15% short interest reflects a well-founded scepticism that the deal synergy story remains more promise than reality.
See the live data behind this article on ORTEX.
Open OMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
